

VAERS Table of Reportable Events Following Vaccination*

Vaccine/Toxoid	Event	Interval from Vaccination
Tetanus in any combination; DTaP, DTP, DTP-HiB, DT, Td, TT	<ul style="list-style-type: none"> A. Anaphylaxis or anaphylactic shock B. Brachial neuritis C. Any sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 7 days 28 days Not applicable See package insert
Pertussis in any combination; DTaP, DTP, DTP-HiB, P	<ul style="list-style-type: none"> A. Anaphylaxis or anaphylactic shock B. Encephalopathy (or encephalitis) C. Any sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 7 days 7 days Not applicable See package insert
Measle, mumps and rubella in any combination; MMR, MR, M, R	<ul style="list-style-type: none"> A. Anaphylaxis or anaphylactic shock B. Encephalopathy (or encephalitis) C. Any sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 7 days 15 days Not applicable See package insert
Rubella in any combination; MMR, MR, R.	<ul style="list-style-type: none"> A. Chronic arthritis B. Any sequela (including death) of above event C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 42 days Not applicable See package insert
Measles in any combination; MMR, MR, M	<ul style="list-style-type: none"> A. Thrombocytopenic purpura B. Vaccine-strain measles viral infection in an immunodeficient recipient C. Any sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 30 days 6 months Not applicable See package insert
Oral Polio (OPV)	<ul style="list-style-type: none"> A. Paralytic polio B. Vaccine-strain polio viral infection C. Any sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 30 days¹/ 6 months² 30 days¹/ 6 months² Not applicable See package insert
Inactivated Polio (IPV)	<ul style="list-style-type: none"> A. Anaphylaxis or anaphylactic shock B. Any sequela (including death) of the above event C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 7 days Not applicable See package insert
Hepatitis B	<ul style="list-style-type: none"> A. Anaphylaxis or anaphylactic shock B. Any sequela (including death) of the above event C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> 7 days Not applicable See package insert
<u>Hemophilus influenzae</u> type b (conjugate)	<ul style="list-style-type: none"> A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> Not applicable See package insert
Varicella	<ul style="list-style-type: none"> A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> Not applicable See package insert
Rotavirus	<ul style="list-style-type: none"> A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> Not applicable See package insert
Pneumococcal conjugate	<ul style="list-style-type: none"> A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine 	<ul style="list-style-type: none"> Not applicable See package insert

Hepatitis A	A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	Not applicable See package insert
Influenza (trivalent)	A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	Not applicable See package insert
Meningococcal	A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	Not applicable See package insert
Human Papillomavirus	A. Any sequela (including death) of the above event B. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	Not applicable See package insert

*The Reportable Events Table (RET) reflects what is reportable by law (42 USC 300aa-25) to the Vaccine Adverse Event Reporting System (VAERS) including conditions found in the manufacturers package insert. In addition, individuals are encouraged to report **any** clinically significant or unexpected events (even if you are not certain the vaccine caused the event) for **any** vaccine, whether or not it is listed on the RET. Manufacturers are also required by regulation (21CFR 600.80) to report to the VAERS program all adverse events made known to them for any vaccine. Effective November 10, 2008.

¹in a non-immunodeficient recipient

²in an immunodeficient recipient